Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

Jazz anklagas för falskspel – går med på förlikning

Irländska Jazz Pharmaceuticals har gått med på att betala 145 miljoner dollar i förlikning efter anklagelser om brott mot amerikanska konkurrenslagar.

Wusson Accelerator AB

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

Tore Duvold tar över vd-posten på Spermosens

Lundbaserade fertilitetsbolaget Spermosens har anställt Tore Duvold som ny verkställande direktör.

Immunterapibolag tar in 339 miljoner

Immunterapibolaget Asgard Therapeutics har tagit in 30 miljoner euro, motsvarande omkring 339 miljoner kronor, i en finanseringsrunda.

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

The Swedish Academy of Sciences: “We have too many researchers”

Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.

Innovativ cellodling lockar investerare till Lundabolag

Lundabolaget Cellevate har säkrat ett finansiellt tillskott på 39 miljoner kronor, som ska bidra till att skynda på kommersialisering och global lansering av fö...

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Skånskt medtech-bolag får ny storägare

Fåhraeus Startup & Growth Fund går in som en av huvudägarna i medtech-bolaget Airsonett.

Astra Zeneca-vd och KI-professor blir rådgivare åt regeringen

Regeringen har nu tillsatt en ny forskningsberedning som består av experter från både akademin och industrin.

Major investment in women’s health – for a more equal healthcare system

”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

“We are Europe’s hotspot in life science”

The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees ...

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportuni...

Spago tankar kassan

Bolaget gör en riktad emission om drygt 18 miljoner kronor.

Follicum tar in 56 miljoner

Emission tar in flera högprofilerade investerare.